Diagnostic performance of RASSF1A and CDKN2A gene methylation versus a-fetoprotein in hepatocellular carcinoma

Hanan Nomeir; Heba Gaber El-Sheredy; Azhar Nomeir; Neveen Mostafa; Shaymaa El-hamshary

doi:10.5114/ceh.2022.119315

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2022
vol. 8

Send email

Copy url:

abstract:

Original paper

Diagnostic performance of RASSF1A and CDKN2A gene methylation versus a-fetoprotein in hepatocellular carcinoma

Hanan Mohamed Nomeir

¹

,

Heba Gaber El-Sheredy

²

,

Azhar Mohamed Nomeir

³

,

Neveen Rashad Mostafa

⁴

,

Shaymaa Ali El-hamshary

⁵

Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Department of Cancer Management and Research, Medical Research Institute, Alexandria University, Alexandria, Egypt
Department of Chemical Pathology, Medical Research Institute, Alexandria University, Alexandria, Egypt
Department of Experimental and Clinical Internal Medicine, Medical Research Institute, Alexandria University, Alexandria, Egypt
Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt

Clin Exp HEPATOL 2022; 8, 3: 243-252

DOI: https://doi.org/10.5114/ceh.2022.119315

Online publish date: 2022/09/16

View full text Get citation

PlumX metrics:

Aim of the study
This study aimed to evaluate the methylation status of two genes in the peripheral blood as possible non-invasive biomarkers for hepatocellular carcinoma (HCC) development in Egyptian patients with hepatitis C virus (HCV)-related liver cirrhosis, compare them with a-fetoprotein (AFP), and assess their relationship with the clinicopathological characteristics of the tumor.

Material and methods
Thirty healthy volunteers, forty patients with HCC on top of HCV-associated liver cirrhosis, and forty patients with HCV-associated liver cirrhosis participated in this study. Using methylation-specific polymerase chain reaction (MSP), the methylation status of RASSF1A and CDKN2A was assessed.

Results
The tumor group was significantly more methylated in both genes than the cirrhosis and the control groups. The RASSF1A gene was highly methylated in advanced tumor characteristics. There was no association between AFP levels in the blood and the methylation state of both genes. The combined diagnostic performance of the methylation status of both genes in predicting HCC in cirrhotic patients was high but not to the degree of that of AFP.

Conclusions
Methylated RASSF1A and CDKN2A levels in the blood may be employed as a non-invasive biomarker for the detection of HCC, especially in high-risk individuals.

keywords:

Diagnostic performance of RASSF1A and CDKN2A gene methylation versus a-fetoprotein in hepatocellular carcinoma

Hanan Mohamed Nomeir 1 , Heba Gaber El-Sheredy 2 , Azhar Mohamed Nomeir 3 , Neveen Rashad Mostafa 4 , Shaymaa Ali El-hamshary 5

epigenetics, DNA methylation, RASSF1A, CDKN2A, HCC

Hanan Mohamed Nomeir

¹

,

Heba Gaber El-Sheredy

²

,

Azhar Mohamed Nomeir

³

,

Neveen Rashad Mostafa

⁴

,

Shaymaa Ali El-hamshary

⁵